Table 2.
Relationship between BAG2 expression and clinicalpathological features of gastric patients from KM-plotter.
| n (%) | BAG2 expression | P-value | ||
|---|---|---|---|---|
| High (%) | Low (%) | |||
| Gender | <0.001 | |||
| Male | 1286 (78.8) | 304 (23.6) | 982 (76.4) | |
| Female | 345 (21.2) | 226 (65.5) | 119 (34.5) | |
| T stage | <0.001 | |||
| T2 | 400 (42.1) | 111 (27.8) | 289(72.3) | |
| T3 | 474 (49.9) | 256 (54.0) | 218 (46.0) | |
| T4 | 76 (8.0) | 30 (39.5) | 46 (60.5) | |
| N status | <0.001 | |||
| N0 | 281 (31.2) | 158 (56.2) | 123 (43.8) | |
| N1–3 | 620 (68.8) | 200 (32.3) | 420 (67.7) | |
| M stage | <0.001 | |||
| M0 | 704 (89.7) | 226 (32.1) | 478 (67.9) | |
| M1 | 81 (10.3) | 56 (69.1) | 25 (30.9) | |
| Clinical stage | <0.001 | |||
| I | 243 (16.4) | 127 (52.3) | 116 (47.7) | |
| II | 251 (16.9) | 68 (27.1) | 183 (72.9) | |
| III | 734 (49.5) | 208 (28.3) | 526 (71.7) | |
| IV | 254 (17.1) | 78 (30.7) | 176 (69.3) | |
| Differentiation | <0.001 | |||
| Well | 86 (13.9) | 24 (27.9) | 62 (72.1) | |
| Moderately | 173 (28.0) | 43 (24.9) | 130 (75.1) | |
| Poorly | 359 (58.1) | 219 (61.0) | 140 (39.0) | |
| Pathology type | 0.813 | |||
| Intestinal | 887 (71.6) | 297 (33.5) | 590 (66.5) | |
| Diffuse | 351 (28.4) | 120 (34.2) | 231 (65.8) | |
| HER2a status | <0.001 | |||
| Negative | 1404 (75.6) | 394 (28.1) | 1010 (71.9) | |
| Positive | 453 (24.4) | 315 (69.5) | 138 (30.5) | |
| Treatment | <0.001 | |||
| Surgery alone | 571 (71.2) | 154 (27.0) | 417 (73.0) | |
| 5-FUb based adjuvant | 231 (28.8) | 172 (74.5) | 59 (25.5) | |
a
HER2, human epidermal growth factor receptor 2.
b
5-FU, 5-Fluorouracil.